Bionexus Gene Lab Stock Technical Analysis
| BGLC Stock | USD 2.60 0.05 1.89% |
As of the 1st of February, BioNexus Gene shows the Mean Deviation of 2.57, risk adjusted performance of (0.19), and Standard Deviation of 3.4. BioNexus Gene Lab technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
BioNexus Gene Momentum Analysis
Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as BioNexus, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to BioNexusBioNexus Gene's Momentum analyses are specifically helpful, as they help investors time the market using mark points where the market can reverse. The reversal spots are usually identified through divergence between price movement and momentum.Will Specialty Chemicals sector continue expanding? Could BioNexus diversify its offerings? Factors like these will boost the valuation of BioNexus Gene. Projected growth potential of BioNexus fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every BioNexus Gene data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth (0.95) | Earnings Share (1.28) | Revenue Per Share | Quarterly Revenue Growth (0.03) | Return On Assets |
The market value of BioNexus Gene Lab is measured differently than its book value, which is the value of BioNexus that is recorded on the company's balance sheet. Investors also form their own opinion of BioNexus Gene's value that differs from its market value or its book value, called intrinsic value, which is BioNexus Gene's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because BioNexus Gene's market value can be influenced by many factors that don't directly affect BioNexus Gene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between BioNexus Gene's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding BioNexus Gene should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, BioNexus Gene's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
BioNexus Gene 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to BioNexus Gene's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of BioNexus Gene.
| 11/03/2025 |
| 02/01/2026 |
If you would invest 0.00 in BioNexus Gene on November 3, 2025 and sell it all today you would earn a total of 0.00 from holding BioNexus Gene Lab or generate 0.0% return on investment in BioNexus Gene over 90 days. BioNexus Gene is related to or competes with Advanced Biomed, Trinity Biotech, Aptorum Group, Beyond Air, Mustang Bio, Galecto, and ReWalk Robotics. BioNexus Gene Lab Corporation, a molecular diagnostics company, focuses on developing and commercializing molecular diag... More
BioNexus Gene Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure BioNexus Gene's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess BioNexus Gene Lab upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.29) | |||
| Maximum Drawdown | 16.78 | |||
| Value At Risk | (7.25) | |||
| Potential Upside | 4.14 |
BioNexus Gene Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for BioNexus Gene's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as BioNexus Gene's standard deviation. In reality, there are many statistical measures that can use BioNexus Gene historical prices to predict the future BioNexus Gene's volatility.| Risk Adjusted Performance | (0.19) | |||
| Jensen Alpha | (0.99) | |||
| Total Risk Alpha | (1.12) | |||
| Treynor Ratio | (0.94) |
BioNexus Gene February 1, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.19) | |||
| Market Risk Adjusted Performance | (0.93) | |||
| Mean Deviation | 2.57 | |||
| Coefficient Of Variation | (359.64) | |||
| Standard Deviation | 3.4 | |||
| Variance | 11.56 | |||
| Information Ratio | (0.29) | |||
| Jensen Alpha | (0.99) | |||
| Total Risk Alpha | (1.12) | |||
| Treynor Ratio | (0.94) | |||
| Maximum Drawdown | 16.78 | |||
| Value At Risk | (7.25) | |||
| Potential Upside | 4.14 | |||
| Skewness | (0.76) | |||
| Kurtosis | 1.01 |
BioNexus Gene Lab Backtested Returns
BioNexus Gene Lab secures Sharpe Ratio (or Efficiency) of -0.34, which signifies that the company had a -0.34 % return per unit of risk over the last 3 months. BioNexus Gene Lab exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm BioNexus Gene's Risk Adjusted Performance of (0.19), mean deviation of 2.57, and Standard Deviation of 3.4 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.01, which signifies a somewhat significant risk relative to the market. BioNexus Gene returns are very sensitive to returns on the market. As the market goes up or down, BioNexus Gene is expected to follow. At this point, BioNexus Gene Lab has a negative expected return of -1.14%. Please make sure to confirm BioNexus Gene's maximum drawdown, daily balance of power, period momentum indicator, as well as the relationship between the skewness and day typical price , to decide if BioNexus Gene Lab performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.77 |
Good predictability
BioNexus Gene Lab has good predictability. Overlapping area represents the amount of predictability between BioNexus Gene time series from 3rd of November 2025 to 18th of December 2025 and 18th of December 2025 to 1st of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of BioNexus Gene Lab price movement. The serial correlation of 0.77 indicates that around 77.0% of current BioNexus Gene price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.77 | |
| Spearman Rank Test | 0.91 | |
| Residual Average | 0.0 | |
| Price Variance | 0.28 |
BioNexus Gene technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
BioNexus Gene Lab Technical Analysis
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Average True Range was developed by J. Welles Wilder in 1970s. It is one of components of the Welles Wilder Directional Movement indicators. The ATR is a measure of BioNexus Gene Lab volatility. High ATR values indicate high volatility, and low values indicate low volatility.
About BioNexus Gene Technical Analysis
The technical analysis module can be used to analyzes prices, returns, volume, basic money flow, and other market information and help investors to determine the real value of BioNexus Gene Lab on a daily or weekly bases. We use both bottom-up as well as top-down valuation methodologies to arrive at the intrinsic value of BioNexus Gene Lab based on its technical analysis. In general, a bottom-up approach, as applied to this company, focuses on BioNexus Gene Lab price pattern first instead of the macroeconomic environment surrounding BioNexus Gene Lab. By analyzing BioNexus Gene's financials, daily price indicators, and related drivers such as dividends, momentum ratios, and various types of growth rates, we attempt to find the most accurate representation of BioNexus Gene's intrinsic value. As compared to a bottom-up approach, our top-down model examines the macroeconomic factors that affect the industry/economy before zooming in to BioNexus Gene specific price patterns or momentum indicators. Please read more on our technical analysis page.
| 2023 | 2024 | 2025 | 2026 (projected) | Payables Turnover | 6.02 | 5.47 | 4.92 | 3.48 | Days Of Inventory On Hand | 49.2 | 61.65 | 70.9 | 98.57 |
BioNexus Gene February 1, 2026 Technical Indicators
Most technical analysis of BioNexus help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for BioNexus from various momentum indicators to cycle indicators. When you analyze BioNexus charts, please remember that the event formation may indicate an entry point for a short seller, and look at different other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.19) | |||
| Market Risk Adjusted Performance | (0.93) | |||
| Mean Deviation | 2.57 | |||
| Coefficient Of Variation | (359.64) | |||
| Standard Deviation | 3.4 | |||
| Variance | 11.56 | |||
| Information Ratio | (0.29) | |||
| Jensen Alpha | (0.99) | |||
| Total Risk Alpha | (1.12) | |||
| Treynor Ratio | (0.94) | |||
| Maximum Drawdown | 16.78 | |||
| Value At Risk | (7.25) | |||
| Potential Upside | 4.14 | |||
| Skewness | (0.76) | |||
| Kurtosis | 1.01 |
BioNexus Gene February 1, 2026 Daily Trend Indicators
Traders often use several different daily volumes and price technical indicators to supplement a more traditional technical analysis when analyzing securities such as BioNexus stock. With literally thousands of different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 0.09 | ||
| Daily Balance Of Power | (0.21) | ||
| Rate Of Daily Change | 0.98 | ||
| Day Median Price | 2.63 | ||
| Day Typical Price | 2.62 | ||
| Price Action Indicator | (0.05) | ||
| Market Facilitation Index | 0.24 |
Complementary Tools for BioNexus Stock analysis
When running BioNexus Gene's price analysis, check to measure BioNexus Gene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNexus Gene is operating at the current time. Most of BioNexus Gene's value examination focuses on studying past and present price action to predict the probability of BioNexus Gene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNexus Gene's price. Additionally, you may evaluate how the addition of BioNexus Gene to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |